Clinical proof-of-concept of the extended half-life that is obtained in this way has been achieved for an anti-IL-6R and anti-TNF VHH fused to a serum albumin-binding VHH, used in the treatment of rheumatoid arthritis. The gene discussed is TNF; the disease is rheumatoid arthritis.